Cybin shares are trading lower. The company announced it has initiated the dosing of the final cohort of its Phase 2 trial evaluating CYB003 in major depressive disorder.
Portfolio Pulse from Benzinga Newsdesk
Cybin Inc. has begun dosing the final cohort of its Phase 2 trial for CYB003 in major depressive disorder. Following this announcement, the company's shares have seen a decrease in value.
August 04, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Cybin's stock price is trading lower following the announcement of the final dosing phase of its CYB003 trial.
The announcement of the final dosing phase of Cybin's CYB003 trial has led to a decrease in the company's stock price. This could be due to investor uncertainty about the outcome of the trial or the potential market for the drug if it is approved.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100